US regulator orders GLP-1 drug makers to warn of rare eye condition linked to blindness

The US Food and Drug Administration has required makers of GLP-1 weight-loss drugs to update product labels with warnings about a rare eye condition. The condition is called NAION, short for non-arteritic anterior ischemic optic neuropathy, and it can lead to blindness. The label requirement covers well-known medications including Ozempic and Wegovy. The move means patients using these drugs will be alerted to the risk through official prescribing information.